A Mixed-Methods Exploratory Pilot Study of the Investigational MYNERVA Leia Sensory Prosthesis in U.S. Adults With Peripheral Neuropathy (MYN-L001-002)
This is a US-specific pilot study to evaluate the short- and long-term effects of the investigational MYNERVA Leia Sensory Prosthesis on gait, neuropathic symptoms and quality of life in US adults with peripheral neuropathy, and to capture insights on the device's usability and perceived clinical effects.
研究概览
详细说明
Through a single, two-hour in-person session per participant, this study is intended to generate preliminary evidence on whether the Leia Sensory Prosthesis improves gait patterns and sensory function in US adults with peripheral neuropathy, based on short-term device use.
A phone follow-up will inform on participant-reported clinical effects of the single use of Leia, and their duration.
Findings will also allow to gain a more comprehensive understanding of US demographic specifics to inform future device design, usability improvements, and potential adoption barriers ahead of further clinical development.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Mississippi
-
Ocean Springs、Mississippi、美国、39564
- Foot Specialists of South Mississippi
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Signed informed consent prior to any study procedure
- Adults ≥ 18 years
- Clinical diagnosis of peripheral neuropathy, confirmed per site procedures
- Gait or balance difficulties as self-reported and confirmed by single-leg stance < 30 seconds
- Able to walk without walking aids
- Stable supplements and medications ≥ 1 month before intervention and willing to maintain stability during 1 month following the intervention
- Willingness and ability to attend the initial in-person session (up to 2 hours) and follow-up calls.
Exclusion Criteria:
- Untreated/unhealed lesions of any kind (e.g., wounds, swelling, infection, inflamed area of skin or eruptions on the lower leg (foot and ankle) or near device use (e.g., untreated lymphedema, phlebitis, thrombo-phlebitis or varicose veins)
- Untreated/unhealed fractures in the foot and ankle
- Cancerous growth in the planned treatment area
- Severe peripheral vascular disease (e.g., gangrene)
- Implanted electrical devices or pacemakers
- Lower-limb orthoses/braces that cannot be removed for assessments
- Pregnant or breast-feeding females
- Usage of other medical devices for the relief of neuropathic symptoms during the study
- Current participation in any other clinical study using an investigational device or investigational drug
- Orthopedic conditions substantially limiting gait (e.g., failed back surgery syndrome (FBSS), recent hip or knee replacement, unstable fractures) as judged by the investigator
- Inability to perceive the stimulation (tested by MYNERVA staff during calibration)
- Cognitive impairment or poor command of English that preclude informed consent or answering questionnaires
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：不适用
- 介入模型：单组作业
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Leia Sensory Prosthesis
Participants use the device during a single supervised session at the clinic |
A non-invasive wearable device used to evaluate the short- and long-term effects on gait, neuropathic symptoms and quality of life in US adults with peripheral neuropathy, and to capture insights on the device's usability and perceived clinical effects. |
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in gait parameters
大体时间：At visit 1 (Day 1) before the intervention and at visit 1 (Day 1) during the single 30 minutes treatment session
|
using the 10-meter walking test |
At visit 1 (Day 1) before the intervention and at visit 1 (Day 1) during the single 30 minutes treatment session
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Single-leg stance
大体时间：At visit 1 (Day 1) before the intervention and at visit 1 (Day 1) during the single 30 minutes treatment session
|
The single-leg stance test is a simple clinical assessment used to evaluate static balance and postural control. The patient is instructed to stand unassisted on one leg for up to 30 seconds, with eyes open and arms by the side. The test is performed in both legs. Inability to maintain the position for 30 seconds indicating impaired balance and increased risk of falls. |
At visit 1 (Day 1) before the intervention and at visit 1 (Day 1) during the single 30 minutes treatment session
|
|
Timed-up and Go (TUG) in seconds
大体时间：At visit 1 (Day 1) before the intervention and at visit 1 (Day 1) during the single 30 minutes treatment session
|
The Timed Up and Go (TUG) test assesses functional mobility. Participants are instructed to stand up from a chair, walk 3 metres at their usual pace, turn around, walk back to the chair, and sit down. The time from the command to start until the participant is seated again is recorded in seconds. A shorter time indicates better functional mobility. |
At visit 1 (Day 1) before the intervention and at visit 1 (Day 1) during the single 30 minutes treatment session
|
|
Sensory function - Monofilament test
大体时间：At visit 1 (Day 1) before the intervention and at visit 1 (Day 1) directly after the single 30 minutes treatment session
|
Sensitivity to pressure and touch |
At visit 1 (Day 1) before the intervention and at visit 1 (Day 1) directly after the single 30 minutes treatment session
|
|
Quality of life (NORFOLK QOL-DN (in part)
大体时间：At visit 1 (Day 1) before the intervention, 1 day after intervention (visit 2), monthly up to max. 6 months (only if patients perceived persisting benefit)
|
Evaluates impact of intervention on daily function and well-being. |
At visit 1 (Day 1) before the intervention, 1 day after intervention (visit 2), monthly up to max. 6 months (only if patients perceived persisting benefit)
|
|
EQ-5D (in part) questionnaire
大体时间：At visit 1 (Day 1) before the intervention, 1 day after intervention (visit 2), monthly up to max. 6 months (only if patients perceived persisting benefit)
|
Evaluates impact of intervention on daily function and well-being. |
At visit 1 (Day 1) before the intervention, 1 day after intervention (visit 2), monthly up to max. 6 months (only if patients perceived persisting benefit)
|
|
Neuropathic pain symptoms (NPSI questionnaire)
大体时间：At visit 1 (Day 1) before the intervention and at visit 1 (Day 1) directly after the single 30 minutes treatment session
|
Captures changes in neuropathic pain intensity and quality. |
At visit 1 (Day 1) before the intervention and at visit 1 (Day 1) directly after the single 30 minutes treatment session
|
|
Patient history including symptoms, patient journey, and treatments received related to peripheral neuropathy
大体时间：At visit 1 (Day 1)
|
Patients are asked for their symptoms, disease progression, diagnostic pathway and treatments received related to peripheral neuropathy |
At visit 1 (Day 1)
|
|
Fall history: fall questionnaire
大体时间：At visit 1 (Day 1) before the intervention
|
Assessment of previous falls |
At visit 1 (Day 1) before the intervention
|
|
Usability and patient satisfaction
大体时间：At visit 1 (Day 1) directly after the single treatment session
|
Patients will provide feedback on usability, comfort and user-friendliness in a patient satisfaction questionaire. |
At visit 1 (Day 1) directly after the single treatment session
|
|
Patient-reported perceived clinical effects after stimulation
大体时间：1 day after intervention (visit 2), monthly until the effect is not persisting anymore or latest at 6 monts (whatever occurrs first)
|
Patients are asked for perceived clinical effect after stimulation via phone call follow-up |
1 day after intervention (visit 2), monthly until the effect is not persisting anymore or latest at 6 monts (whatever occurrs first)
|
|
Safety Outcome
大体时间：At visit 1 (Day 1) during the single 30 minutes treatment session until the maximal 6 months follow-up period ends
|
All Adverse events (AEs): incidence, severity, seriousness, relatedness to device/procedures |
At visit 1 (Day 1) during the single 30 minutes treatment session until the maximal 6 months follow-up period ends
|
|
Safety Outcome
大体时间：At visit 1 (Day 1) during the single 30 minutes treatment session until the maximal 6 months follow-up period ends
|
All Device deficiencies: number, type, corrective actions |
At visit 1 (Day 1) during the single 30 minutes treatment session until the maximal 6 months follow-up period ends
|
合作者和调查者
赞助
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.